Skip to main content

Table 2 Sensitivity and specificity of autoantibodies before onset of disease symptoms in individuals who later developed SLEa

From: Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden

  Presymptomatic individuals      
Autoantibodies Sensitivity, n(%) Specificity n% Controls, n(%) OR 95% CI Pvalueb LR
ANA 16 (45.7)*** 95.0 10 (6.7) 11.5 4.54 to 28.87 <0.0001 9.14
dsDNA 7 (20.0)*** 98.7 2 (1.4) 18.13 3.58 to 91.84 <0.0001 15.38
Ro/SSA 7 (20.0)*** 97.4 4 (2.7) 8.94 2.45 to 32.58 <0.0001 5.56
Histone 5 (14.3)** 98.0 3 (2.0) 8.06 1.83 to 35.54 <0.001 7.15
RNP 4 (11.4)** 98.7 2 (1.4) 9.36 1.64 to 53.36 <0.01 8.77
La/SSB 3 (8.6)** 100 0     
Jo-1 3 (8.6)* 98.7 2 (1.4) 6.80 1.09 to 42.36 <0.05 6.62
Scl-70 2 (5.7) 99.3 1 (0.7) 8.85 0.78 to 100.51 ns 8.0
Sm 1 (2.9) 100 0     
Centromere protein B (2.9) 98.7 1 (0.7) 4.29 0.26 to 70.39 ns 1.54
  1. a95% CI, 95% confidence interval; bP values were determined by using χ2 test or Fisher's exact test as appropriate. . * = p < 0.05, **= p < 0.01, ***= p < 0.001
  2. ANA, antinuclear antibody; dsDNA, double-stranded DNA; Jo-1, anti-histidyl-tRNA synthetase antibody; La/SSB, anti-Sjögren's syndrome antigen B; LR, positive likelihood value; ns, not significant; OR, odds ratio; RNP, ribonucleoprotein; Ro/SSA, anti-Sjögren's syndrome antigen A; Scl-70, scleroderma 70; Sm, Smith.